NovoCure (NVCR) Stock Forecast & Price Target

Compare

1,555 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NVCR Analyst Ratings

Moderate Buy

2 Buy

2 Hold

0 Sell

Based on 4 analysts giving stock ratings to

NovoCure

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NVCR Stock 12 Month Forecast

Average Price Target

$27.00

▲(104.24% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for NovoCure in the last 3 months. The average price target is $27.00 with a high forecast of $42.00 and a low forecast of $18.00. The average price target represents a 104.24% change from the last price of $13.22.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","43":"$43","18.25":"$18.25","26.5":"$26.5","34.75":"$34.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,18.25,26.5,34.75,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.68,14.012307692307692,16.344615384615384,18.676923076923075,21.00923076923077,23.341538461538462,25.673846153846153,28.006153846153843,30.338461538461537,32.67076923076923,35.00307692307692,37.33538461538461,39.667692307692306,{"y":42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.68,12.858461538461539,14.036923076923078,15.215384615384615,16.393846153846155,17.572307692307692,18.75076923076923,19.92923076923077,21.107692307692307,22.286153846153844,23.464615384615385,24.643076923076922,25.82153846153846,{"y":27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.68,12.166153846153845,12.652307692307692,13.138461538461538,13.624615384615385,14.11076923076923,14.596923076923076,15.083076923076923,15.569230769230769,16.055384615384614,16.54153846153846,17.027692307692305,17.513846153846153,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.85,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.52,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.52,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.95,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.19,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.81,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.68,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$42.00

Average Price Target$27.00

Lowest Price Target$18.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emily Bodnar

H.C. Wainwright

$42

Buy

217.70%

Upside

Reiterated

12/01/25

NovoCure's Strategic Leadership and Product Developments Drive Buy RatingOur Buy rating and $42 price target are based on a discounted cash flow analysis (DCF). In our DCF, we extend our estimates to 2038 and assign a 12% discount rate and -25% terminal value, given that we view Novocure's technology as a platform. We are currently modeling 2L NSCLC with 100% POS, brain mets from NSCLC with 80% POS, and pancreatic cancer with 70%, and have not included other pipeline assets or indications in our valuation.

Jessica Fye

J.P. Morgan

$25→$23

Hold

73.98%

Upside

Reiterated

10/27/25

Novocure price target lowered to $23 from $25 at JPMorganNovocure price target lowered to $23 from $25 at JPMorgan

David Nierengarten

Wedbush

$18

Hold

36.16%

Upside

Reiterated

10/13/25

Wedbush Remains a Hold on NovoCure (NVCR)

Vijay Kumar

Evercore ISI

$25

Buy

89.11%

Upside

Reiterated

10/07/25

Evercore ISI Sticks to Their Buy Rating for NovoCure (NVCR)

Jason Bednar

Piper Sandler

$34

Buy

157.19%

Upside

Reiterated

08/29/25

Piper Sandler Sticks to Their Buy Rating for NovoCure (NVCR)

Larry Biegelsen

Wells Fargo

$40→$14.5

Hold

9.68%

Upside

Downgraded

07/25/25

Novocure downgraded to Equal Weight from Overweight at Wells FargoNovocure downgraded to Equal Weight from Overweight at Wells Fargo

Jonathan Chang

Leerink Partners

$33

Buy

149.62%

Upside

Reiterated

07/25/25

Positive Outlook for NovoCure: Strong Financial Performance and Promising Pipeline Developments

Kevin DeGeeter

Ladenburg Thalmann & Co.

$30

Buy

126.93%

Upside

Initiated

07/08/25

Novocure initiated with a Buy at LadenburgNovocure initiated with a Buy at Ladenburg

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emily Bodnar

H.C. Wainwright

$42

Buy

217.70%

Upside

Reiterated

12/01/25

Jessica Fye

J.P. Morgan

$25→$23

Hold

73.98%

Upside

Reiterated

10/27/25

Novocure price target lowered to $23 from $25 at JPMorganNovocure price target lowered to $23 from $25 at JPMorgan

David Nierengarten

Wedbush

$18

Hold

36.16%

Upside

Reiterated

10/13/25

Wedbush Remains a Hold on NovoCure (NVCR)

Vijay Kumar

Evercore ISI

$25

Buy

89.11%

Upside

Reiterated

10/07/25

Evercore ISI Sticks to Their Buy Rating for NovoCure (NVCR)

Jason Bednar

Piper Sandler

$34

Buy

157.19%

Upside

Reiterated

08/29/25

Piper Sandler Sticks to Their Buy Rating for NovoCure (NVCR)

Larry Biegelsen

Wells Fargo

$40→$14.5

Hold

9.68%

Upside

Downgraded

07/25/25

Novocure downgraded to Equal Weight from Overweight at Wells FargoNovocure downgraded to Equal Weight from Overweight at Wells Fargo

Jonathan Chang

Leerink Partners

$33

Buy

149.62%

Upside

Reiterated

07/25/25

Positive Outlook for NovoCure: Strong Financial Performance and Promising Pipeline Developments

Kevin DeGeeter

Ladenburg Thalmann & Co.

$30

Buy

126.93%

Upside

Initiated

07/08/25

Novocure initiated with a Buy at LadenburgNovocure initiated with a Buy at Ladenburg

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NovoCure

1 Month

xxx

Success Rate

13/26 ratings generated profit

Average Return

-0.35%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -0.35% per trade.

3 Months

xxx

Success Rate

15/26 ratings generated profit

Average Return

+7.78%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.69% of your transactions generating a profit, with an average return of +7.78% per trade.

1 Year

Jonathan ChangLeerink Partners

Success Rate

6/16 ratings generated profit

Average Return

-8.15%

reiterated a buy rating 5 months ago

Copying Jonathan Chang's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -8.15% per trade.

2 Years

xxx

Success Rate

3/16 ratings generated profit

Average Return

-28.64%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 18.75% of your transactions generating a profit, with an average return of -28.64% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NVCR Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NVCR has received 3 Buy Ratings, 6 Hold Ratings, and 1 Sell Ratings. NVCR average Analyst price target in the past 3 months is 27.00.

Each month's total comprises the sum of three months' worth of ratings.

NVCR Financial Forecast

NVCR Earnings Forecast

Next quarter’s earnings estimate for NVCR is -$0.40 with a range of -$0.50 to -$0.31. The previous quarter’s EPS was -$0.33. NVCR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year NVCR has Performed in-line its overall industry.

NVCR Sales Forecast

Next quarter’s sales forecast for NVCR is $168.31M with a range of $158.28M to $178.40M. The previous quarter’s sales results were $167.20M. NVCR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year NVCR has Performed in-line its overall industry.

NVCR Stock Forecast FAQ

What is NVCR’s average 12-month price target, according to analysts?

Based on analyst ratings, NovoCure Ltd’s 12-month average price target is 27.00.

What is NVCR’s upside potential, based on the analysts’ average price target?

NovoCure Ltd has 104.24% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NVCR a Buy, Sell or Hold?

NovoCure Ltd has a consensus rating of Moderate Buy which is based on 2 buy ratings, 2 hold ratings and 0 sell ratings.

What is NovoCure Ltd’s price target?

The average price target for NovoCure Ltd is 27.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $42.00 ,the lowest forecast is $18.00. The average price target represents 104.24% Increase from the current price of $13.22.

What do analysts say about NovoCure Ltd?

NovoCure Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of NVCR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

NovoCure (NVCR) Stock Forecast & Price Target

NVCR Analyst Ratings

NVCR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering NovoCure

NVCR Analyst Recommendation Trends

NVCR Financial Forecast

NVCR Earnings Forecast

NVCR Sales Forecast

NVCR Stock Forecast FAQ

Detailed List of Analyst Forecasts